Tag: 1

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI^® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.¹

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for real power gains in 2025
In the evolving world of performance fitness, strength building isn’t just about lifting heavier—it’s about training smarter, fueling properly, and choosing science-backed supplements that support sustainable muscle growth. As more athletes, fitness enthusiasts, and bodybuilders shift away from synthetic enhancers, a natural powerhouse is gaining serious ground: CrazyBulk strength training supplements.

ATLANTA, GA, July 28, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, today issues the following statement to its common stock shareholders.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired UnitedHealth securities between December 3, 2024 and April 16, 2025, both dates inclusive (the “Class Period”). Investors have until July 7, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Performance Highlights